| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA827: Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy |
|
Medicine details |
|
| Medicine name | azacitidine (Onureg®) |
| Formulation | 200 mg, 300 mg tablet |
| Reference number | 4913 |
| Indication | Maintenance therapy in adult patients with acute myeloid leukaemia (AML) who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (HSCT) |
| Company | Celgene Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 14/05/2021 |
| NICE guidance | TA827: Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy |